The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502).
 
Frank A. Sinicrope
Stock and Other Ownership Interests - illumina
Honoraria - American Society of Clinical Oncology; Imedex
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Roche (Inst); Ventana Medical Systems (Inst)
Research Funding - Ventana Medical Systems (Inst)
Travel, Accommodations, Expenses - ventana medical systems
 
Fang-Shu Ou
No Relationships to Disclose
 
Tyler Zemla
No Relationships to Disclose
 
Andrew B. Nixon
Consulting or Advisory Role - Kanghong Pharma; Lilly; Pfizer
Research Funding - Acceleron Pharma; Amgen; AstraZeneca/MedImmune; Eureka Therapeutics; Genentech/Roche; Leadiant Biosciences; medpacto; Novartis; Seagen; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Patent (Inst); Patent Pending (Inst)
Travel, Accommodations, Expenses - TRACON Pharma
 
Kabir Mody
Consulting or Advisory Role - AstraZeneca; Celgene; Eisai; Genentech/Roche; Merrimack; Vicus Therapeutics
Research Funding - Agios; ARIAD; ArQule; FibroGen; MedImmune; Senhwa Biosciences; Taiho Pharmaceutical; TRACON Pharma
 
Alexandra Levasseur
No Relationships to Disclose
 
Amylou C. Dueck
Consulting or Advisory Role - Bayer; Phytogine
Travel, Accommodations, Expenses - Pfizer
 
Asha R. Dhanarajan
No Relationships to Disclose
 
Christopher Hanyoung Lieu
Consulting or Advisory Role - Foundation Medicine
Other Relationship - Immune Design
 
Deirdre Jill Cohen
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Merck Sharp & Dohme; Taiho Pharmaceutical; Vicus Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Merck (Inst)
 
Federico Innocenti
Patents, Royalties, Other Intellectual Property - Royalties from the Mayo Foundation on the UGT1A1 testing
 
Robert J. Behrens
No Relationships to Disclose
 
Walter Peters
No Relationships to Disclose
 
Nicolas Sommer
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - 3DMedcare (I); Agios (I); Alignmed (I); Amgen (I); Antengene (I); Aptus Clinical; Aptus Clinical (I); ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); BeiGene (I); BiolineRx; Boston Scientific (I); Bridgebio (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CARsgen Therapeutics (I); CASI Pharmaceuticals (I); CASI Pharmaceuticals (I); Celgene; Celgene (I); Celsion (I); Cipla (I); CytomX Therapeutics; Daiichi Sankyo (I); Debiopharm Group (I); Delcath Systems (I); Eisai (I); Exelixis (I); Genoscience Pharma (I); Gilead Sciences; Halozyme; Halozyme (I); Hengrui Medicine (I); Inovio Pharmaceuticals (I); Ipsen (I); Janssen; Jazz Pharmaceuticals (I); Kyowa Hakko Kirin (I); LAM Therapeutics (I); Lilly (I); Loxo; Merck (I); Merrimack; Minapharma (I); Newlink Genetics; Novella Clinical (I); Onxeo (I); PCI Biotech (I); Pfizer; Pharmacyclics; Pharmacyte Biotech; Pieris Pharmaceuticals; QED Therapeutics (I); RedHill Biopharma (I); Sanofi; Sanofi (I); Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); SOBI; Targovax; Tekmira (I); twoXAR; twoXAR (I); VAXIMM; Vicus Therapeutics (I); Yakult Pharmaceutical (I); Yakult Pharmaceutical (I); Yiviva (I)
Research Funding - Acta Biologica (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Halozyme (Inst); Mabvax (Inst); OncoQuest (Inst); OncoQuest (Inst); Roche (Inst)
 
Jeffrey A. Meyerhardt
Honoraria - Chugai Pharma; Cota Healthcare; Ignyta; Taiho Pharmaceutical
Research Funding - Boston Biomedical (Inst)